Skip to content

Tetracycline Versus Doxycycline for HP Rescue Therapy

Bismuth Quadruple Therapy With Tetracycline Versus Doxycycline as Rescue Therapy for Helicobacter Pylori Infection: a Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05018923
Enrollment
242
Registered
2021-08-24
Start date
2021-08-24
Completion date
2022-12-30
Last updated
2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Brief summary

This randomized controlled clinical trial will evaluate the efficacy and safety of proton pump inhibitor, bismuth, metronidazole, and either tetracycline or doxycycline for Helicobacter pylori rescue treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori.

Interventions

DRUGRabeprazole

20mg bid

DRUGBismuth potassium citrate

0.6g bid

DRUGMetronidazole

0.4g qid

DRUGDoxycycline

0.1g bid

DRUGTetracycline

0.5g qid

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF). * 18-75 years old on the day of signing the ICF. * Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test. * Have failed eradication treatment before.

Exclusion criteria

* Have not received Hp eradication treatment. * Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases. * Subjects or guardians refused to participate in the trial. * Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment. * Have taken antibiotics, bismuth, PPI or Chinese traditional medicine 4 weeks before treatment. * Pregnant or lactating women. * Active peptic ulcer. * allergic to drugs used in the trial. * any other circumstances that are not suitable for recruitment.

Design outcomes

Primary

MeasureTime frameDescription
Eradication rate of Helicobacter pyloriAt least 4 weeks after completion of therapyEradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value).

Secondary

MeasureTime frameDescription
Eradication rate of Helicobacter pylori susceptible strainsAt least 4 weeks after completion of therapyEradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic susceptible strains were assessed using the E test method.
Eradication rate of Helicobacter pylori resistant strainsAt least 4 weeks after completion of therapyEradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic resistant strains were assessed using the E test method.

Other

MeasureTime frameDescription
Adherence rate2 weeks during therapyAdherence was defined as poor when subjects took less than 80% of the total medication.
Frequency of adverse events2 weeks during therapyAny possible adverse events during the 14-day treatment period were recorded.

Countries

China

Contacts

Primary ContactQi Chen, MD
chenqimd@163.com86-17811921405

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026